RE:Cipher Selling US drug assetsThe thought just occurred to me that Crescita will launch Pliaglis in the US, Mexico and Canada in Q1 of 2017.
Earlier in one of my posts (https://www.stockhouse.com/companies/bullboard?symbol=t.ctx&postid=25225970 ) , I estimated 2015 sales of pliaglis in the US, by Galderma at $18.5 million US.
In that year, Galderma added a few salemen which were directly focussed on pushing US sales volumes.
But the sales effort was marginal.
With a dedicated sales force and effective marketing, Pliaglis could achieve its $50 million US sales target.
Pliaglis is a skin drug and Cipher has its US dermatology drug assets up for sale , if not the entire company.
Crescita's CFO recently ...coincident with the acquisition of Intega ,, left and joined Cipher.
That seems to be an odd move given that Cipher just announced its strategic iniatives.
Here is my take.
GUD will buy Ciphers Canadian drug assets ( $40 million in revenues ) coincident with Crescita's acquisition of Ciphers US assets.
GUD is already Crescita largest shareholder and has licensed some of Crescita dermatology products for international sales.
GUD's CEO was recently appointed to Crescita's BOD.
It makes so much common sense that I will go out on a limb and say that Crescita will one way or another acquire Ciphers US drug assets along with 28 detail salesmen and that Lemieux will return to Crescita as head of its US operations.